{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]}],"title":"Pulse rate; decrease to <60"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"}]}],"title":"Pulse rate; Change to normal/no change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"3"}]}],"title":"Pulse rate; increase to >100"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"12"}],"units":"Participants"}],"description":"Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is \\<60 beats per minute and \\>100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Participants were counted twice if the participant \"Decreased to \\<60\" and \"Increased to \\>100\" post-baseline.","groups":[{"description":"Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG000","title":"Participants With NMC"},{"description":"Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Participants With SCLC"},{"description":"Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG002","title":"Participants With CRPC"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG003","title":"Participants With TNBC"},{"description":"Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG004","title":"Participants With ER+BC"},{"description":"Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG005","title":"Participants With GIST"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population. Only those participants with data available at Baseline and the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure","title":"Number of Participants With Changes in Pulse Rate From Baseline-Part 2","type":"PRIMARY","unitOfMeasure":"Participants"}